Adaptive resistance is the term that describes this scenario in which cancer cells utilize augmented PD-1/PD-L1 signaling, with PD-L1 upregulated by IFN-γ secreted by immune cells, to thwart the anti-tumor immune response [93]. The gene discussed is CD274; the disease is cancer.